FACTOR CERTIFICATE - MODERNA | Real-time Euronext Paris 15:09:58 16/05/2024 BST | ||
| 34.25 EUR | +13.98% |
|
| Current month | +51.16% | ||
| 1 month | +97.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 16/05/24 | 34.25 | +13.98% |
| 15/05/24 | 30.05 | -7.42% |
| 14/05/24 | 32.46 | +21.98% |
| 13/05/24 | 26.61 | +18.27% |
| 10/05/24 | 22.5 | -21.90% |
Real-time Euronext Paris
Last update May 16, 2024 at 03:09 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| Y899S | |
| ISIN | DE000SU1EYZ0 |
| Date issued | 01/11/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 52.72 € |
|---|---|
| Lowest since issue | 5.25 € |
| Spread | 0.37 € |
| Spread % | 1.15% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
129.1
USD
Average target price
138.5
USD
Spread / Average Target
+7.32%
- Stock Market
- Certificates
- Y899S Certificat
